Want to see PTKFY full AI Analyst Report?
PTKFY Stock Chart & Stats
$7.76
$0.00(0.00%)
At close: 4:00 PM EDT
$7.76
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$7.32 - $17.82
Previous CloseN/A
Volume159.00
Average Volume (3M)154.00
Market Cap
$1.89B
Enterprise Value$1.78K
Total Cash (Recent Filing)$4.53T
Total Debt (Recent Filing)$304.45B
Price to Earnings (P/E)9.1
Beta0.42
Next Earnings
Nov 03, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield2.48%
Share Statistics
EPS (TTM)16104.00
Shares Outstanding234,066,960
10 Day Avg. Volume0
30 Day Avg. Volume154
Financial Highlights & Ratios
PEG Ratio0.91
Price to Book (P/B)2.19
Price to Sales (P/S)1.45
P/FCF Ratio20.78
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Very Low Leverage / Strong Balance SheetExceptionally low debt and steadily building equity materially reduce financial distress risk and preserve strategic optionality. This durability supports steady capital allocation for R&D, dividends, acquisitions or cycles without reliance on external financing, strengthening long-term resilience.
Diversified Healthcare Business And Distribution NetworkMultiple product divisions and a nationwide distribution arm provide structural revenue diversification and scale benefits. Cross-channel reach and distribution monetization reduce single-segment dependency, support stable volumes across cycles, and enable efficient go-to-market execution over months to years.
Solid Profitability And ReturnsHealthy margins and mid‑teens ROE indicate durable operating economics versus peers. Sustained profitability underpins internal cash generation, funds reinvestment or shareholder distributions, and allows the company to withstand modest revenue shocks while maintaining strategic investments.
Bears Say
Slowing Revenue GrowthA marked deceleration in top-line growth reduces the firm's ability to expand earnings organically and limits operating leverage. If sustained, slower revenue trends constrain upside to margins and ROE, placing greater reliance on cost cuts, mix changes, or inorganic growth to restore prior growth trajectories.
Weakened Cash ConversionOperating cash flow lagging reported earnings and mildly negative FCF growth signal worsening earnings quality or working-capital strains. Persisting weak cash conversion would limit organic funding for capex, M&A, or dividends and reduce flexibility despite a strong balance sheet.
Margin Drift Versus Prior PeaksGradual margin compression suggests rising cost pressures or pricing constraints. If the trend continues, it will erode net income and ROE, forcing reliance on volume growth or efficiency initiatives to restore margin levels—both uncertain in the medium term.
PT Kalbe Farma Tbk News
PTKFY FAQ
What was PT Kalbe Farma Tbk’s price range in the past 12 months?
PT Kalbe Farma Tbk lowest stock price was $7.32 and its highest was $17.82 in the past 12 months.
What is PT Kalbe Farma Tbk’s market cap?
PT Kalbe Farma Tbk’s market cap is $1.89B.
When is PT Kalbe Farma Tbk’s upcoming earnings report date?
PT Kalbe Farma Tbk’s upcoming earnings report date is Nov 03, 2026 which is in 91 days.
How were PT Kalbe Farma Tbk’s earnings last quarter?
PT Kalbe Farma Tbk released its earnings results on Jul 31, 2026. The company reported $0.223 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is PT Kalbe Farma Tbk overvalued?
According to Wall Street analysts PT Kalbe Farma Tbk’s price is currently Overvalued.
Does PT Kalbe Farma Tbk pay dividends?
PT Kalbe Farma Tbk pays a Annually dividend of $0.223 which represents an annual dividend yield of 2.48%. See more information on PT Kalbe Farma Tbk dividends here
What is PT Kalbe Farma Tbk’s EPS estimate?
PT Kalbe Farma Tbk’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does PT Kalbe Farma Tbk have?
PT Kalbe Farma Tbk has 234,066,960 shares outstanding.
What happened to PT Kalbe Farma Tbk’s price movement after its last earnings report?
PT Kalbe Farma Tbk reported an EPS of $0.223 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 4.813%.
Which hedge fund is a major shareholder of PT Kalbe Farma Tbk?
Currently, no hedge funds are holding shares in PTKFY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
PT Kalbe Farma Tbk Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-33.75%
12-Months-Change
Fundamentals
Return on Equity
2.48%
Trailing 12-Months
Asset Growth
0.52%
Trailing 12-Months
Company Description
PT Kalbe Farma Tbk
PT Kalbe Farma Tbk is engaged in the development, distribution, and trading of pharmaceutical products. It operates through the following divisions: Prescription Pharmaceutical, Consumer Health, Nutritionals, and Distribution and Logistic. The Prescription Pharmaceutical division offers generic drugs, branded generics, and licensed drugs, which are distributed to hospitals, pharmacies, and drug stores. The Consumer Health division includes over-the-counter drugs, consumer products, food supplements, preventive products, energy drinks, and healthy ready-to-drink products. The Nutritionals division sells biscuits, cereals, and milk products for infants, toddlers, children, pre-teenagers, adults, expectant and lactating mothers, and elderly; as well as nutritional products for consumers with special medical needs. The Distribution and Logistic division maintains distribution of the company's and third party principal's products across Indonesia; and focuses on the trading of raw material, medical devices, and retail health service. The company founded by Boenyamin Setiawan on September 10, 1966 and is headquartered in Jakarta, Indonesia.
Technical Analysis
Grifols SA
―
SRx Health Solutions
―
Scilex Holding Company
―
Organon
―
Citius Oncology
―
Ownership Overview
―
Insiders
―
Mutual Funds
0.03% Other Institutional Investors
99.97% Public Companies and
Individual Investors